Waters Corporation (WATERS CORP) - 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for the period ended March 31, 2001. Waters Corporation is the world's largest manufacturer and distributor of high performance liquid chromatography (HPLC) instruments, chromatography columns, and related services. Through subsidiaries Micromass and TA Instruments, the Company also leads in mass spectrometry and thermal analysis. The three operating segments are aggregated into one reporting segment.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Net Sales | $201.0 million | $180.2 million |
| Gross Profit | $127.7 million | $113.9 million |
| Gross Margin | 63.5% | 63.2% |
| Operating Income | $49.0 million | $41.3 million |
| Net Income | $38.4 million | $19.3 million |
| Diluted EPS | $0.28 | $0.14 |
| Cash from Operations | $24.6 million | $35.2 million |
| Cash and Equivalents (End of Period) | $89.2 million | $2.2 million |
| Total Debt (Notes Payable) | $2.3 million | $4.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% year-over-year. Excluding currency effects, sales grew 17%, driven by life science customers in mass spectrometry and HPLC lines. Currency translation reduced reported growth by 5 percentage points due to a weaker euro and yen.
- Profitability: Operating income rose 19% to $49.0 million, aided by sales growth and productivity improvements. The effective tax rate decreased to 24% from 26% due to a favorable shift in taxable income mix.
- Cash Flow: Operating cash flow decreased to $24.6 million from $35.2 million. This was primarily due to working capital needs, including $15.3 million used for accounts receivable and inventory growth (specifically new product inventory) and $11.6 million used for decreased accounts payable.
- Accounting Change: The Q1 2000 results included a cumulative effect charge of $10.8 million related to a change in revenue recognition (SAB 101). This non-recurring item significantly depressed the prior year's net income and EPS.
Guidance, Outlook, and Risks
- Outlook: Management expects existing cash balances ($89.2 million) and operating cash flows to be sufficient to fund working capital and capital spending. No dividends are planned.
- Product Pipeline: Thermal analysis sales grew in the low single digits in advance of a revamped product line introduced in March 2001.
- Legal Proceedings: The Company is involved in several patent disputes (Perkin-Elmer, Hewlett-Packard, Cohesive Technologies, Viscotek). Management believes it has meritorious arguments and that outcomes will not be material to the Company.
- Market Risks: Risks include changes in the analytical instrument marketplace, competitive pricing, and the ability to generate sales from new products. There have been no material changes in market risk regarding foreign currency or interest rates.
Investor Verification Checklist
- Verify the sustainability of the 17% organic sales growth rate in the HPLC and mass spectrometry segments.
- Monitor the impact of the new thermal analysis product line introduced in March 2001 on future revenue.
- Review the status of ongoing patent litigation, particularly the Perkin-Elmer and Hewlett-Packard cases, for potential future costs or injunctions.
- Assess the impact of foreign currency fluctuations on future earnings, given the 5 percentage point drag in the current quarter.
- Confirm the Company's ability to manage working capital requirements as inventory builds for new product launches.